Form 4: Revolution Medicines Exec Sells Shares for Tax Withholding

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,157 shares of common stock on June 16, 2026, to cover tax withholding obligations related to vested restricted stock units.

Summary

• Jeff Cislini, General Counsel at Revolution Medicines, Inc., reported a transaction on June 16, 2026.
• The transaction involved the sale of 2,157 shares of common stock.
• This sale was executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligations upon the vesting of restricted stock units (RSUs).
• The weighted average sale price was $156.1191 per share, with individual trades ranging from $156.1105 to $156.8251.
• Following the transaction, Cislini beneficially owns 56,521 shares of common stock.
• This ownership includes 43,514 RSUs and 160 shares acquired through the Employee Stock Purchase Plan on May 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a standard procedural transaction for tax purposes under a pre-established plan, not indicative of management's view on the company's future prospects.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful selling.
• The sale was for tax withholding purposes, a common and expected event for executives receiving stock-based compensation.
• The reporting person retains a significant number of shares (56,521) after the transaction.

Negatives

• A portion of the executive's holdings was sold, which could be perceived negatively by some investors, although it was for tax purposes.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The sale of shares by an executive, even for tax purposes, can sometimes be interpreted as a lack of confidence in future stock performance, though this is a standard procedure.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance. It solely reports a past transaction.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are a routine event for executives in the biotechnology and pharmaceutical sectors, especially following significant vesting of equity awards. This transaction, executed under a 10b5-1 plan, is standard practice and does not inherently signal a negative outlook for Revolution Medicines.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related event for an executive and is unlikely to have a significant direct impact on the share price, though any insider selling can be a point of observation.

Next Steps

• No specific next steps for the company are mentioned in this filing.
• The reporting person will continue to hold the remaining beneficial ownership of Revolution Medicines stock.

Key Dates

Keywords

Revolution Medicines, RVMD, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, Rule 10b5-1, Jeff Cislini, Beneficial Ownership